Lixisenatide/insulin glargine regulatory update

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 12-2 to recommend approval of iGlarLixi lixisenatide/insulin glargine from

Read the full 174 word article

User Sign In